Clear Point Neuro, Inc. CLPT
We take great care to ensure that the data presented and summarized in this overview for ClearPoint Neuro, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLPT
View all-
Black Rock Inc. New York, NY1.47MShares$8.43 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.31MShares$7.48 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA513KShares$2.93 Million0.0% of portfolio
-
Taylor Frigon Capital Management LLC424KShares$2.43 Million1.38% of portfolio
-
State Street Corp Boston, MA416KShares$2.38 Million0.0% of portfolio
-
Cm Management, LLC375KShares$2.15 Million2.21% of portfolio
-
Brown Advisory Inc333KShares$1.91 Million0.0% of portfolio
-
Essex Investment Management CO LLC Boston, MA330KShares$1.89 Million0.46% of portfolio
-
Cahill Wealth Management, LLC Portage, MI244KShares$1.4 Million0.97% of portfolio
-
Northern Trust Corp Chicago, IL198KShares$1.13 Million0.0% of portfolio
Latest Institutional Activity in CLPT
Top Purchases
Top Sells
About CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Insider Transactions at CLPT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 10
2024
|
Joseph Michael Burnett CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
14,003
-5.32%
|
$70,015
$5.74 P/Share
|
Jun 10
2024
|
Danilo D'Alessandro Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,824
-9.0%
|
$24,120
$5.74 P/Share
|
Jun 10
2024
|
L. Jeremy Stigall Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,502
-5.25%
|
$12,510
$5.74 P/Share
|
May 14
2024
|
Pascal E R Girin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+19.2%
|
-
|
May 14
2024
|
R John Fletcher Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+15.72%
|
-
|
May 14
2024
|
Lynnette C Fallon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+36.37%
|
-
|
May 14
2024
|
Timothy T. Richards Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+21.79%
|
-
|
May 14
2024
|
Linda M. Liau Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+36.16%
|
-
|
May 14
2024
|
B Kristine Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+31.32%
|
-
|
May 14
2024
|
Matthew B. Klein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,153
+36.83%
|
-
|
Apr 01
2024
|
Timothy T. Richards Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,640
+3.56%
|
$9,840
$6.8 P/Share
|
Apr 01
2024
|
Linda M. Liau Director |
BUY
Grant, award, or other acquisition
|
Direct |
436
+3.21%
|
$2,616
$6.8 P/Share
|
Apr 01
2024
|
Pascal E R Girin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,056
+1.88%
|
$6,336
$6.8 P/Share
|
Apr 01
2024
|
R John Fletcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
850
+1.12%
|
$5,100
$6.8 P/Share
|
Mar 06
2024
|
Danilo D'Alessandro Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,718
-8.09%
|
$28,308
$6.24 P/Share
|
Mar 06
2024
|
Danilo D'Alessandro Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,383
+13.86%
|
-
|
Mar 06
2024
|
L. Jeremy Stigall Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,180
-6.25%
|
$19,080
$6.24 P/Share
|
Mar 06
2024
|
L. Jeremy Stigall Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,889
+14.87%
|
-
|
Mar 06
2024
|
Mazin Sabra Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,463
-7.31%
|
$20,778
$6.24 P/Share
|
Mar 06
2024
|
Mazin Sabra Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,913
+12.74%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 25.9K shares |
---|---|
Exercise of conversion of derivative security | 169K shares |
Payment of exercise price or tax liability | 66.4K shares |
---|